U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C19H25NOS.ClH
Molecular Weight 351.934
Optical Activity ( - )
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ROTIGOTINE HYDROCHLORIDE

SMILES

Cl.CCCN(CCC1=CC=CS1)[C@H]2CCC3=C(C2)C=CC=C3O

InChI

InChIKey=CEXBONHIOKGWNU-NTISSMGPSA-N
InChI=1S/C19H25NOS.ClH/c1-2-11-20(12-10-17-6-4-13-22-17)16-8-9-18-15(14-16)5-3-7-19(18)21;/h3-7,13,16,21H,2,8-12,14H2,1H3;1H/t16-;/m0./s1

HIDE SMILES / InChI
Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE
Molecular Formula C19H25NOS
Molecular Weight 315.473
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: description was created based on several sources, including: https://www.drugs.com/mtm/rotigotine-transdermal.html http://www.rxlist.com/neupro-drug.htm http://www.wikidoc.org/index.php/Rotigotine

Rotigotine is an agonist at all 5 dopamine receptor subtypes (D1-D5) but binds to the D3 receptor with the highest affinity. It is also an antagonist at α-2-adrenergic receptors and an agonist at the 5HT1A receptors. Rotigotine also inhibits dopamine uptake and prolactin secretion. It is FDA approved for the treatment of Parkinson's disease, restless legs syndrome. Dopamine antagonists, such as antipsychotics or metoclopramide, may diminish the effectiveness of Rotigotine. Common adverse reactions include nausea, vomiting, somnolence, application site reactions, dizziness, anorexia, hyperhidrosis, insomnia and dyskinesia.

CNS Activity

Originator

Approval Year

2007
205
Targets

Targets

Primary TargetPharmacologyConditionPotency
Agonist
2678
 13.5 nM [Ki]
Agonist
2678
 83.0 nM [Ki]
Agonist
2678
 5.4 nM [Ki]
Agonist
2678
 15.0 nM [Ki]
Agonist
2678
 30.0 nM [Ki]
Antagonist
2778
 27.0 nM [Ki]
Agonist
2678
 0.7 nM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8429
NEUPRO

Approved Use

NEUPRO is a dopamine agonist indicated for the treatment of: Parkinson's disease (1.1) Moderate-to-severe primary Restless Legs Syndrome (1.2) 1.1 Parkinson's Disease (PD) NEUPRO is indicated for the treatment of Parkinson's disease. 1.2 Restless Legs Syndrome (RLS) NEUPRO is indicated for the treatment of moderate-to-severe primary Restless Legs Syndrome.

Launch Date

2007
Primary
Approved
8429
NEUPRO

Approved Use

NEUPRO is a dopamine agonist indicated for the treatment of: Parkinson's disease (1.1) Moderate-to-severe primary Restless Legs Syndrome (1.2) 1.1 Parkinson's Disease (PD) NEUPRO is indicated for the treatment of Parkinson's disease. 1.2 Restless Legs Syndrome (RLS) NEUPRO is indicated for the treatment of moderate-to-severe primary Restless Legs Syndrome.

Launch Date

2007
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
0.34 ng/mL
REVIEW
https://pubmed.ncbi.nlm.nih.gov/25795100/
3 mg 2 times / day steady-state, transdermal
dose: 3 mg
route of administration: Transdermal
experiment type: STEADY-STATE
co-administered:
ROTIGOTINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
4.63 ng × h/mL
REVIEW
https://pubmed.ncbi.nlm.nih.gov/25795100/
3 mg 2 times / day steady-state, transdermal
dose: 3 mg
route of administration: Transdermal
experiment type: STEADY-STATE
co-administered:
ROTIGOTINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
6.5 h
REVIEW
https://pubmed.ncbi.nlm.nih.gov/25795100/
3 mg 2 times / day steady-state, transdermal
dose: 3 mg
route of administration: Transdermal
experiment type: STEADY-STATE
co-administered:
ROTIGOTINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
10%
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021829s019lbl.pdf
unknown
 ROTIGOTINE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
54 mg 1 times / day multiple, topical
Highest studied dose
Dose: 54 mg, 1 times / day
Route: topical
Route: multiple
Dose: 54 mg, 1 times / day
Sources:
https://www.google.ru/url?sa=t&rct=j&q=&esrc=s&source=web&cd=&ved=2ahUKEwitvqTfk73vAhXLl4sKHSWZATIQFjAIegQIBhAD&url=https%3A%2F%2Fwww.tga.gov.au%2Ffile%2F1344%2Fdownload&usg=AOvVaw2Ldihm6CIUQh4H_1DXihmQ
Page: p.10
unhealthy, 29 - 88
n = 130
Health Status: unhealthy
Condition: Advanced-stage Parkinson’s disease
Age Group: 29 - 88
Sex: M+F
Population Size: 130
Sources:
https://www.google.ru/url?sa=t&rct=j&q=&esrc=s&source=web&cd=&ved=2ahUKEwitvqTfk73vAhXLl4sKHSWZATIQFjAIegQIBhAD&url=https%3A%2F%2Fwww.tga.gov.au%2Ffile%2F1344%2Fdownload&usg=AOvVaw2Ldihm6CIUQh4H_1DXihmQ
Page: p.10
Sources:
https://www.google.ru/url?sa=t&rct=j&q=&esrc=s&source=web&cd=&ved=2ahUKEwitvqTfk73vAhXLl4sKHSWZATIQFjAIegQIBhAD&url=https%3A%2F%2Fwww.tga.gov.au%2Ffile%2F1344%2Fdownload&usg=AOvVaw2Ldihm6CIUQh4H_1DXihmQ
Page: p.10
24 mg 1 times / day multiple, topical
Studied dose
Dose: 24 mg, 1 times / day
Route: topical
Route: multiple
Dose: 24 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/19644228
Page: p.196
unhealthy, 68.8
n = 26
Health Status: unhealthy
Condition: Advanced-stage Parkinson’s disease
Age Group: 68.8
Sex: M+F
Population Size: 26
Sources:
https://pubmed.ncbi.nlm.nih.gov/19644228
Page: p.196
Disc. AE: Abnormal ECG, Hypertension...
AEs leading to
discontinuation/dose reduction:
Abnormal ECG (mild, 3.85%)
Hypertension (mild, 3.85%)
Sensory hallucinations (moderate, 3.85%)
Application site reaction (moderate, 7.7%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/19644228
Page: p.196
8 mg 1 times / day multiple, topical
Recommended
Dose: 8 mg, 1 times / day
Route: topical
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021829s002lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Advanced-stage Parkinson’s disease
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021829s002lbl.pdf
Page: p.1
Disc. AE: Allergic reaction, Somnolence...
AEs leading to
discontinuation/dose reduction:
Allergic reaction
Somnolence
Hallucinations
Psychotic behavior
Dyskinesia
Hypotension symptomatic
Syncope
Blood pressure increased
Tachycardia
Impulse-control disorder
Compulsive personality disorder
Daytime sleepiness
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021829s002lbl.pdf
Page: p.1
8 mg 1 times / day multiple, topical
Recommended
Dose: 8 mg, 1 times / day
Route: topical
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021829s002lbl.pdf
Page: p.1, p.5
unhealthy
Health Status: unhealthy
Condition: Advanced-stage Parkinson’s disease
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021829s002lbl.pdf
Page: p.1, p.5
Disc. AE: Application site reaction...
AEs leading to
discontinuation/dose reduction:
Application site reaction (2%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021829s002lbl.pdf
Page: p.1, p.5
AEs

AEs

AESignificanceDosePopulation
Abnormal ECG mild, 3.85%
Disc. AE
24 mg 1 times / day multiple, topical
Studied dose
Dose: 24 mg, 1 times / day
Route: topical
Route: multiple
Dose: 24 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/19644228
Page: p.196
unhealthy, 68.8
n = 26
Health Status: unhealthy
Condition: Advanced-stage Parkinson’s disease
Age Group: 68.8
Sex: M+F
Population Size: 26
Sources:
https://pubmed.ncbi.nlm.nih.gov/19644228
Page: p.196
Hypertension mild, 3.85%
Disc. AE
24 mg 1 times / day multiple, topical
Studied dose
Dose: 24 mg, 1 times / day
Route: topical
Route: multiple
Dose: 24 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/19644228
Page: p.196
unhealthy, 68.8
n = 26
Health Status: unhealthy
Condition: Advanced-stage Parkinson’s disease
Age Group: 68.8
Sex: M+F
Population Size: 26
Sources:
https://pubmed.ncbi.nlm.nih.gov/19644228
Page: p.196
Sensory hallucinations moderate, 3.85%
Disc. AE
24 mg 1 times / day multiple, topical
Studied dose
Dose: 24 mg, 1 times / day
Route: topical
Route: multiple
Dose: 24 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/19644228
Page: p.196
unhealthy, 68.8
n = 26
Health Status: unhealthy
Condition: Advanced-stage Parkinson’s disease
Age Group: 68.8
Sex: M+F
Population Size: 26
Sources:
https://pubmed.ncbi.nlm.nih.gov/19644228
Page: p.196
Application site reaction moderate, 7.7%
Disc. AE
24 mg 1 times / day multiple, topical
Studied dose
Dose: 24 mg, 1 times / day
Route: topical
Route: multiple
Dose: 24 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/19644228
Page: p.196
unhealthy, 68.8
n = 26
Health Status: unhealthy
Condition: Advanced-stage Parkinson’s disease
Age Group: 68.8
Sex: M+F
Population Size: 26
Sources:
https://pubmed.ncbi.nlm.nih.gov/19644228
Page: p.196
Allergic reaction Disc. AE
8 mg 1 times / day multiple, topical
Recommended
Dose: 8 mg, 1 times / day
Route: topical
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021829s002lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Advanced-stage Parkinson’s disease
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021829s002lbl.pdf
Page: p.1
Blood pressure increased Disc. AE
8 mg 1 times / day multiple, topical
Recommended
Dose: 8 mg, 1 times / day
Route: topical
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021829s002lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Advanced-stage Parkinson’s disease
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021829s002lbl.pdf
Page: p.1
Compulsive personality disorder Disc. AE
8 mg 1 times / day multiple, topical
Recommended
Dose: 8 mg, 1 times / day
Route: topical
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021829s002lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Advanced-stage Parkinson’s disease
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021829s002lbl.pdf
Page: p.1
Daytime sleepiness Disc. AE
8 mg 1 times / day multiple, topical
Recommended
Dose: 8 mg, 1 times / day
Route: topical
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021829s002lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Advanced-stage Parkinson’s disease
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021829s002lbl.pdf
Page: p.1
Dyskinesia Disc. AE
8 mg 1 times / day multiple, topical
Recommended
Dose: 8 mg, 1 times / day
Route: topical
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021829s002lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Advanced-stage Parkinson’s disease
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021829s002lbl.pdf
Page: p.1
Hallucinations Disc. AE
8 mg 1 times / day multiple, topical
Recommended
Dose: 8 mg, 1 times / day
Route: topical
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021829s002lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Advanced-stage Parkinson’s disease
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021829s002lbl.pdf
Page: p.1
Hypotension symptomatic Disc. AE
8 mg 1 times / day multiple, topical
Recommended
Dose: 8 mg, 1 times / day
Route: topical
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021829s002lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Advanced-stage Parkinson’s disease
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021829s002lbl.pdf
Page: p.1
Impulse-control disorder Disc. AE
8 mg 1 times / day multiple, topical
Recommended
Dose: 8 mg, 1 times / day
Route: topical
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021829s002lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Advanced-stage Parkinson’s disease
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021829s002lbl.pdf
Page: p.1
Psychotic behavior Disc. AE
8 mg 1 times / day multiple, topical
Recommended
Dose: 8 mg, 1 times / day
Route: topical
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021829s002lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Advanced-stage Parkinson’s disease
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021829s002lbl.pdf
Page: p.1
Somnolence Disc. AE
8 mg 1 times / day multiple, topical
Recommended
Dose: 8 mg, 1 times / day
Route: topical
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021829s002lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Advanced-stage Parkinson’s disease
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021829s002lbl.pdf
Page: p.1
Syncope Disc. AE
8 mg 1 times / day multiple, topical
Recommended
Dose: 8 mg, 1 times / day
Route: topical
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021829s002lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Advanced-stage Parkinson’s disease
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021829s002lbl.pdf
Page: p.1
Tachycardia Disc. AE
8 mg 1 times / day multiple, topical
Recommended
Dose: 8 mg, 1 times / day
Route: topical
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021829s002lbl.pdf
Page: p.1
unhealthy
Health Status: unhealthy
Condition: Advanced-stage Parkinson’s disease
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021829s002lbl.pdf
Page: p.1
Application site reaction 2%
Disc. AE
8 mg 1 times / day multiple, topical
Recommended
Dose: 8 mg, 1 times / day
Route: topical
Route: multiple
Dose: 8 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021829s002lbl.pdf
Page: p.1, p.5
unhealthy
Health Status: unhealthy
Condition: Advanced-stage Parkinson’s disease
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021829s002lbl.pdf
Page: p.1, p.5
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
inhibitor
1587

inducer
781

substrate
1737
inhibitor
1767

inducer
389
inhibitor
1852
inhibitor
1612

OverviewOther

Other InhibitorOther SubstrateOther Inducer
CYP1A2
1524

CYP2C19
1478

P-gp
1461
UGT1A9
380

UGT2B15
203

CYP2C19
991

SULT1A3
27

UGT1A1
418

UGT1A3
422

UGT1A4
347

UGT1A6
307

UGT1A7
236

UGT2B4
249

UGT2B7
389

UGT2B17
213

UGT1A8
283

UGT1A10
291

CYP1A2
1054
CYP1A2
701

CYP2C19
293
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
CYP1A2
1692
 no
CYP1A2
1692
 no
CYP2C19
1553
 no
CYP2C19
1553
 no
CYP2C9
1819
 no
CYP2C9
1819
 no
CYP2D6
1891
 no
CYP3A4
1925
 no
CYP3A4
1925
 no
P-gp
1650
 no
no (co-administration study)
Comment: rotigone did not influence the transport of digoxin
Page: 50.0
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
UGT1A10
291
 minor [Km >1000 uM]
UGT1A8
283
 minor [Km >1000 uM]
UGT1A1
418
 no
UGT1A3
422
 no
UGT1A4
347
 no
UGT1A6
307
 no
UGT1A7
236
 no
UGT2B17
213
 no
UGT2B4
249
 no
UGT2B7
389
 no
CYP1A2
1054
 yes
CYP2C19
991
 yes
CYP3A4
1737
 yes
SULT1A3
27
 yes
UGT1A9
380
 yes
UGT2B15
203
 yes
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
hERG
1647
Sourcing

Sourcing

Vendor/AggregatorIDURL
AA Blocks
AA0039VR
https://www.aablocks.com/goods/Goods/detail?id=AA0039VR
AK Scientific, Inc. (AKSCI)
2696AH
http://www.aksci.com/item_detail.php?cat=2696AH
Aaron Chemicals
AR003ANJ
http://www.aaronchem.com/99755-59-6
AbMole Bioscience
M3675
http://www.abmole.com/products/rotigotine.html
Achemtek
0102-020374
http://www.achemtek.com/99755-59-6
Adooq BioScience
A11553
https://www.adooq.com/rotigotine.html
Alichem
169006390
http://www.alichem.com/en/products/99755-59-6.html
ApexBio Technology
A3776
http://www.apexbt.com/rotigotine.html
Ark Pharma Scientific Limited
H-015999
http://www.arkpharmtech.com/product/21054.html
Aurora Fine Chemicals LLC
A24.076.584
http://online.aurorafinechemicals.com/info?ID=A24.076.584
Aurum Pharmatech LLC
W-5179
http://www.Aurumpharmatech.com/Product/ProductDetails/W_5179
AvaChem Scientific
2566B
http://www.avachem.com/productSearch.asp?2566B
Axon MedChem
1040
https://www.axonmedchem.com/product/1040
BioSynth
J-502471
https://www.biosynth.com/en/products/all-products/products/J-502471.html
Boerchem
BC677693
http://www.boerchem.com/?product_39574.html
Capot Chemical
16423
http://www.capotchem.com/en/16423.htm
Capot Chemical
PubChem16423
http://www.capotchem.com/en/16423.htm
Chem Scene
CS-0376
http://www.chemscene.com/99755-59-6.html
ChemMol
30109750
http://www.chemmol.com/chemmol/30109750.html
ChemMol
44006753
http://www.chemmol.com/chemmol/44006753.html
ChemMol
44009998
http://www.chemmol.com/chemmol/44009998.html
ChemMol
49406931
http://www.chemmol.com/chemmol/49406931.html
Chemspace
CSSB00015192657
https://chem-space.com/CSSB00015192657
DC Chemicals
DC22619
http://www.dcchemicals.com/product_show-DC22619.html
Excenen
EX-A1164
http://www.excenen.com/searchresultlist.php?id=99755-59-6
LGC Standards
LGCFOR1403.00
https://www.lgcstandards.com/US/en/p/LGCFOR1403.00
LGC Standards
MM1403.00
https://www.lgcstandards.com/US/en/p/MM1403.00
Lab Network
LN01343330
https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN01343330
Matrix Scientific
133323
https://www.matrixscientific.com/133323.html
MedChem Express
HY-75502
https://www.medchemexpress.com/rotigotine.html
MuseChem
A000135
https://www.musechem.com/product/A000135.html
OChem
23571
http://www.ocheminc.com/index.php?act=psearch&pid=572R932
Renno Tech
RL06136
http://www.rennotech.com/product_show.asp?id=6384
Smolecule
S541846
http://www.smolecule.com/products/s541846
Synblock Inc
SB19528
http://www.synblock.com/product/99755-59-6.html
THE BioTek
bt-282084
https://www.thebiotek.com/product/inhibitors/bt-282084
THE BioTek
bt-459851
https://www.thebiotek.com/product/others/bt-459851
Yuhao Chemical
XJ6723
http://www.chemyuhao.com/99755-59-6.html
abcr GmbH
AB462946
http://www.abcr.com/shop/en/AB462946
eNovation Chemicals
Y0991885
https://www.enovationchem.com/ProductDetails.asp?ProductID=Y0991885
PubMed

PubMed

TitleDatePubMed
Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1.
1991 Apr 18
Affinity for dopamine D2, D3, and D4 receptors of 2-aminotetralins. Relevance of D2 agonist binding for determination of receptor subtype selectivity.
1996 Oct 11
Further characterization of structural requirements for ligands at the dopamine D(2) and D(3) receptor: exploring the thiophene moiety.
2002 Jul 4
Rotigotine transdermal patch in the treatment of Parkinson's disease and restless legs syndrome.
2007 Jun
[Restless-legs syndrome].
2008 Aug-Sep
Three-month subchronic intramuscular toxicity study of rotigotine-loaded microspheres in Cynomolgus monkeys.
2013 Feb
Patents

Patents

08614337
2
20020106410
9
20040116537
2
20050079206
2

Sample Use Guides

In Vivo Use Guide
Parkinson’s disease: Initially, 2 mg/24 hours for early-stage disease or 4 mg/24 hours for advanced-stage disease. The dose may be increased as needed by 2 mg/24 hours at weekly intervals, up to 6 mg/24 hours for earlystage disease and up to 8 mg/24 hours for advanced-stage disease. Restless Legs Syndrome: Initially, 1 mg/24 hours, increased as needed by 1 mg/24 hours at weekly intervals, up to 3 mg/24 hours.
Route of Administration: Transdermal
In Vitro Use Guide
The binding of [3H]N-0437 (specific activity 80.6 Ci/mmol) to calf caudate membranes is described. It was found that [3H]N-0437 binds with a high affinity (KD = 0.17 nM) and a low proportion of non-specific binding.
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:55:31 GMT 2023
Edited
by admin
on Fri Dec 15 15:55:31 GMT 2023
Record UNII
6Q1W9573L2
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ROTIGOTINE HYDROCHLORIDE
MI  
Common Name English
ROTIGOTINE HYDROCHLORIDE [MI]
Common Name English
1-NAPHTHALENOL, 5,6,7,8-TETRAHYDRO-6-(PROPYL(2-(2-THIENYL)ETHYL)AMINO)-, HYDROCHLORIDE (1:1), (6S)-
Systematic Name English
(-)-5,6,7,8-TETRAHYDRO-6-(PROPYL(2-(2-THIENYL)ETHYL)AMINO)-1-NAPHTHOL HYDROCHLORIDE
Systematic Name English
ROTIGOTINE HYDROCHLORIDE [USP-RS]
Common Name English
ROTIGOTINE HYDROCHLORIDE, (-)-
Common Name English
Code System Code Type Description
DRUG BANK
DBSALT000155
Created by admin on Fri Dec 15 15:55:31 GMT 2023 , Edited by admin on Fri Dec 15 15:55:31 GMT 2023
PRIMARY
RS_ITEM_NUM
1606079
Created by admin on Fri Dec 15 15:55:31 GMT 2023 , Edited by admin on Fri Dec 15 15:55:31 GMT 2023
PRIMARY
PUBCHEM
59226
Created by admin on Fri Dec 15 15:55:31 GMT 2023 , Edited by admin on Fri Dec 15 15:55:31 GMT 2023
PRIMARY
CAS
125572-93-2
Created by admin on Fri Dec 15 15:55:31 GMT 2023 , Edited by admin on Fri Dec 15 15:55:31 GMT 2023
PRIMARY
EPA CompTox
DTXSID80154792
Created by admin on Fri Dec 15 15:55:31 GMT 2023 , Edited by admin on Fri Dec 15 15:55:31 GMT 2023
PRIMARY
FDA UNII
6Q1W9573L2
Created by admin on Fri Dec 15 15:55:31 GMT 2023 , Edited by admin on Fri Dec 15 15:55:31 GMT 2023
PRIMARY
MERCK INDEX
m9674
Created by admin on Fri Dec 15 15:55:31 GMT 2023 , Edited by admin on Fri Dec 15 15:55:31 GMT 2023
PRIMARY Merck Index
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966